
|Articles|August 28, 2015
New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review
Author(s)Davy James, Managing Editor
Top stories of the week on Specialty Pharmacy Times.
Advertisement
[<a href="//storify.com/pharmacytimes/pcsk9-approval-biosimilar-cost" target="_blank">View the story "New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review" on Storify</a>]
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen–Naproxen Combination for 12-Hour Pain Relief
2
Two Weeks In: What the Medicare GLP-1 Bridge Actually Looks Like at the Counter
3
Up to 5 Cups of Coffee Daily Safe—and Beneficial—for Most Adults
4
Thoracic Radiotherapy Added to Atezolizumab Raises Fatal Toxicity Risk in ES-SCLC
5












































































































